Main menu


Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expansion of Partnership with NW PharmaTech Ltd.

TORONTO, Ontario–(Newsfile Corp. – October 6, 2022) – Satellos Bioscience Inc. (TSXV:MSCL) (“Sateros” or “Ltd.) announced today that its wholly-owned subsidiaries, Amphotericin B Technologies Inc. (“AmpB Tech”) and NW PharmaTech Ltd. (“NWPT”), have established a joint venture, NW Micelle Therapeutics Inc. (“NWMT”). I will. ), with the aim of developing an oral formulation of cannabidiol (“oral CBD”) for the treatment of insomnia and other indications in the field of mental health.

NWPT will arrange and provide the funding needed by NWMT for oral CBD development already underway at the University of Toronto. AmpB Tech licenses certain rights in its patent-protected drug delivery technology, OralTrans™, to his NWMT for use in developing oral CBD. The parties will share ownership of NWMT, with NWPT owning 85% and AmpB Tech 15%. AmpB Tech’s ownership interests are entitled to seats on NWMT’s Board of Directors and are subject to certain anti-dilution protections. Under the terms of the arrangement between the parties, NWPT will obtain a term call option of up to 24 months from Sateros to acquire his AmpB Tech for his US$3 million, and Sateros will make his decision to NWPT. Get a put option that triggers the sale of AmpB Tech. Also, at the end of 24 months he will be paid US$3,000,000.

“Today’s announcement represents an important and significant step forward in our partnership with NWPT, which we have been moving forward for months and which we hope will bring tangible benefits to Satellos shareholders. The team assembled a group of world-leading scientists to advise, said William Jarosz, President and CEO of AmpB Tech.

“We are pleased to extend our partnership with AmpB Tech, and we are pleased to deepen our relationship with its parent company, Satellos. We share our passion for new approaches with them and we look forward to working together.Together we have successfully unlocked the true potential of cannabidiol to help patients in need. said Filipp Korentsvit, one of the founding partners and CEO of NW PharmaTech.

“We believe our expanded bilateral relationship with NWPT provides a realistic and exciting route to generating meaningful returns from iCo’s legacy assets. NWPT’s vision for Oral CBD is impressive and I We are thrilled to partner with them and all the success,” commented Frank Gleeson, President and CEO of Satellos.

About NW Pharmatech Limited
NW PharmaTech is a clinical-stage biopharmaceutical company with a “Nature to Medicine” strategy. The company uses clinical research and the latest technological developments in the pharmaceutical industry to bring to market a new generation of medicines based on natural compounds with unique and promising therapeutic properties.

The company is dedicated to improving the lives of patients by providing new therapies that harness the benefits of natural compounds through new and improved generations of drug delivery formulations. NWPT’s focus on improving the formulation and delivery of the cannabinoid CBD, with significantly improved delivery and stability, represents an opportunity to fully exploit the compound’s therapeutic value clinically.

To achieve this, we aim to provide medicines that truly improve the lives of millions of patients.

For more information, please visit our website

About Sateros Biosciences
Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle disease. Our scientists have discovered what is believed to be the previously unrecognized root cause of skeletal muscle degeneration. What has the potential to change the way muscle disorders are treated. Our Scientific Founder, Dr. Michael Rudnicki, has discovered and demonstrated how muscle stem cells regulate muscle repair and growth throughout life. Leader. He argues that defects in the process known as stem cell “polarity,” which controls how muscle stem cells divide to create muscle progenitor cells, can lead to Duchenne-type failures in muscle regeneration and potentially other muscle groups. Due to the continuous inability to generate sufficient numbers of new muscle cells, the muscles of Duchenne patients are unable to respond and repair the continuous and cumulative damage they experience. Satellos’ lead program is focused on developing oral therapeutics (i.e. pills) aimed at correcting muscle stem cell polarity and restoring the body’s natural muscle repair and regeneration processes. I’m putting We believe our proprietary therapeutic approach is a potential disease-modifying treatment for Duchenne and other dystrophies and offers new hope for patients. To expand our program to other degenerative muscle conditions or disorders, Satellos created a unique discovery platform, his MyoReGenX™. We will use this to identify disease situations in which defects in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. For more information about potential collaborations with Sateros on Sateros’ drug discovery platform and therapeutic candidates, or about its subsidiary Amphotericin B Technologies Inc., please contact Ryan Mitchell, PhD, Director – Business Development at Contact us or visit

contact address:
Christina Cameron
communication director
Sateros Bioscience Co., Ltd.

Notice Regarding Forward-Looking Statements:
This press release contains forward-looking information or forward-looking statements within the meaning of Canadian and US securities laws regarding Sateros and its business. This includes, but is not limited to, statements regarding the potential benefits of modulating stem cell polarity. future impact on Duchenne patients and muscle regeneration in general; projected benefits of Satellos therapeutic approaches, including small molecule drug candidates. Sateros Technologies and Drug Development Programs. Timeline to start human clinical trials. Planned advancement of Sateros research and development. Also, our priorities and expected achievement of drug molecule milestones and evaluation plans. All statements, including, but not limited to, statements regarding future estimates, plans, programs, projections, forecasts, objectives, assumptions, expectations or beliefs regarding future performance or information that is not historical fact are considered “forward-looking statements.” any information or description relating to Often, but not always, forward-looking information or statements are referred to as “ongoing”, “intended”, “planned”, “expects”, “intends”, “forecasts” or “ presumed, “believe,” “hope,” “objective,” “possibly,” “possibly,” “progress,” “develop,” “explore,” “breakthrough.” “probably”, “milestone”, “further”, “prospect”, or any variation of such words or phrases (including negative variations), or that a particular action, event, or outcome is “likely” stating, “could”, “could”, “could”, “could”, or “could”, result or achieved . Such statements are based on our management’s current expectations and views of future events. They are based on assumptions and are subject to risks and uncertainties. Although management believes the assumptions underlying these statements are reasonable, they may prove to be incorrect. Future events and conditions discussed in this release are subject to known and unknown risk factors and uncertainties that affect us, including risks associated with the pharmaceutical and bioscience industries, general market conditions and the stock market. may not occur as a result of giving , and may vary significantly. , economic factors and the ability of management to generally manage and operate the Company’s business. Although Sateros has attempted to identify important factors that could cause its actual actions, events or results to differ materially from those set forth in the forward-looking statements, Satros There may be other factors that cause differences from those expected, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. Forward-looking statements cannot be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and Sateros does not make forward-looking statements as a result of new information, undertakes no obligation to publicly update or revise any statements regarding event, or otherwise.

No regulatory authority has approved or disapproved of the contents of this press release. Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit